Aura Biosciences, Inc. Lease, Cost
Aura Biosciences, Inc. (AURA) reported Lease, Cost of $1.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-11
- Aura Biosciences, Inc. lease, cost for the quarter ending 2026-06-30 was $1.61M, a 37.66% increase year-over-year.
- Aura Biosciences, Inc. lease, cost for the quarter ending 2026-03-31 was $1.40M, a 23.50% increase year-over-year.
- Aura Biosciences, Inc. lease, cost for the quarter ending 2025-12-31 was $1.96M, a 70.82% increase year-over-year.
- Aura Biosciences, Inc. lease, cost for the quarter ending 2025-09-30 was $1.16M, a 2.11% increase year-over-year.
- Aura Biosciences, Inc. lease, cost for fiscal 2025 was $5.43M, a 15.48% increase from fiscal 2024.
- Aura Biosciences, Inc. lease, cost for fiscal 2024 was $4.70M, a 6.69% increase from fiscal 2023.
- Aura Biosciences, Inc. lease, cost for fiscal 2023 was $4.41M, a 40.13% increase from fiscal 2022.
- Aura Biosciences, Inc. lease, cost for fiscal 2022 was $3.15M, a 265.27% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.61M 10-Q · filed 2026-08-11 | $3.02M 10-Q · filed 2026-08-11 | $4.98M derived: sum of 3 quarters · filed 2026-08-11 | $6.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-11 | $3.36M derived: sum of 2 quarters · filed 2026-05-11 | $4.53M derived: sum of 3 quarters · filed 2026-05-11 | $5.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.12M derived: sum of 2 quarters · filed 2026-03-30 | $4.29M derived: sum of 3 quarters · filed 2026-08-11 | $5.43M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-13 | $2.33M derived: sum of 2 quarters · filed 2026-08-11 | $3.47M 10-Q · filed 2025-11-13 | $4.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.17M 10-Q · filed 2026-08-11 | $2.31M 10-Q · filed 2026-08-11 | $3.46M derived: sum of 3 quarters · filed 2026-08-11 | $4.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.14M 10-Q · filed 2026-05-11 | $2.28M derived: sum of 2 quarters · filed 2026-05-11 | $3.42M derived: sum of 3 quarters · filed 2026-05-11 | $4.57M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.29M derived: sum of 2 quarters · filed 2026-03-30 | $3.43M derived: sum of 3 quarters · filed 2026-03-30 | $4.70M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.14M 10-Q · filed 2025-11-13 | $2.29M derived: sum of 2 quarters · filed 2025-11-13 | $3.55M 10-Q · filed 2025-11-13 | $4.61M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.15M 10-Q · filed 2025-08-13 | $2.42M 10-Q · filed 2025-08-13 | $3.47M derived: sum of 3 quarters · filed 2025-08-13 | $4.57M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.23M 10-Q · filed 2025-05-15 | $2.33M derived: sum of 2 quarters · filed 2025-05-15 | $3.43M derived: sum of 3 quarters · filed 2025-05-15 | $4.53M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.20M derived: sum of 2 quarters · filed 2025-03-24 | $3.30M derived: sum of 3 quarters · filed 2025-03-24 | $4.41M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.10M 10-Q · filed 2024-11-12 | $2.20M derived: sum of 2 quarters · filed 2024-11-12 | $3.31M 10-Q · filed 2024-11-12 | $4.63M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.10M 10-Q · filed 2024-08-08 | $2.21M 10-Q · filed 2024-08-08 | $3.53M derived: sum of 3 quarters · filed 2024-08-08 | $4.79M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-09 | $2.43M derived: sum of 2 quarters · filed 2024-05-09 | $3.69M derived: sum of 3 quarters · filed 2024-05-09 | $4.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $2.50M derived: sum of 2 quarters · filed 2024-03-27 | $2.81M derived: sum of 3 quarters · filed 2024-03-27 | $3.15M 10-K · filed 2024-03-27 |
| 2022-09-30 | $1.26M 10-Q · filed 2023-11-09 | $1.58M derived: sum of 2 quarters · filed 2023-11-09 | $1.91M 10-Q · filed 2023-11-09 | $2.16M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $318.00K 10-Q · filed 2023-08-09 | $650.00K 10-Q · filed 2023-08-09 | $897.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.14M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $332.00K 10-Q · filed 2023-05-11 | $579.00K derived: sum of 2 quarters · filed 2023-05-11 | $823.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.03M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $491.00K derived: sum of 2 quarters · filed 2023-03-15 | $699.00K derived: sum of 3 quarters · filed 2023-03-15 | $861.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $244.00K 10-Q · filed 2022-11-10 | $452.00K derived: sum of 2 quarters · filed 2022-11-10 | $614.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $208.00K 10-Q · filed 2022-08-11 | $369.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $161.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |